Senseera a Israeli based biotech startup has raises $7.1M seed funding

Senseera, a Jerusalem-based biotech startup, announced the successful closing of its $7.1 million seed funding round. The round was led by Lightspeed Venture Partners, with investments from I-Next Capital and the Lowy Medical Research Institute.

Company Overview

Founded in 2022, Senseera is on the forefront of developing next-generation liquid biopsy solutions. Its lead GEM BIOMARKERS™ platform decodes cell-specific gene expression and cell states through a simple blood draw based on chromatin epigenomics. This new technique allows for non-invasive biopsy-level precision, thus allowing early detection and monitoring of a host of diseases.

The seed funding round, which amounts to $7.1 million, was led by Lightspeed Venture Partners, a prominent venture capital firm known for backing innovative startups. I-Next Capital and the Lowy Medical Research Institute also participated in the round, both of which have a history of investing in groundbreaking medical technologies.

Read also: AusperBio Therapeutics Completes $73 Million Series B

This capital will be used for several strategic initiatives:

Advancement of the GEM BIOMARKERS™ Platform: The funds will accelerate the development of Senseera’s proprietary platform, enhancing its capabilities in providing detailed molecular insights for diagnosing and monitoring diseases.

• Clinical Trials and Regulatory Approvals: A portion of the investment will be allocated to conducting comprehensive clinical trials to validate the platform’s efficacy and secure necessary regulatory approvals for market entry.
• Expansion of Partnerships: Senseera looks forward to the expansion of partnerships with global biopharmaceutical companies, taking its technology into a faster acceleration in drug development and precision medicine initiatives.

The GEM BIOMARKERS ™ Platform

Its GEM BIOMARKERS™ platform uses cfChIP-seq technology, which looks at cell-free chromatin fragments in the bloodstream that enable the assessment of cell-specific gene expression patterns and state in an individual without the need for invasive tissue biopsies. The platform has been validated extensively through a comprehensive dataset of over 20,000 human samples and findings published in reputable journals such as Nature Biotechnology.

Applications in Disease Diagnostics

This multi-purpose nature makes the technology adaptable to several streams of medical study:

• Liver Disorders: This ranges from a high of 25% prevalence worldwide, wherein diagnostic procedures include often invasive biopsies or not very specific tests. The senseera’s device provides for the non-invasive early diagnosis and care of conditions like MASLD/MASH, which was known earlier as NAFLD/NASH, rejection post-liver transplantation, and hepatocellular carcinoma (HCC). CALCALIST 
• Oncology: By monitoring solid tumor and immune cell states simultaneously in cancer diagnostics, the platform brings insights into all the tumor-immune interactions, providing a critical perspective for the establishment of personalized strategies for treatment.
• Immunology and Metabolic Diseases: Understanding complex immune responses and metabolic disorders through the de-coding cell-specific gene expressions, the platform supports the designing of targeted therapies for the same diseases.

Read also: PeptiSystems a biotech startup has successfully raised €3.92M funding

Strategic Importance of the Investment

This round is important to Senseera and, more broadly, to the biotech landscape:

• Validation of Technology: The investment by such a distinguished set of venture capital firms marks confidence in the innovative approach that Senseera has to liquid biopsy diagnostics.
• Accelerated Market Entry: Senseera, with this secured funding, is well-positioned to expedite commercialization, bringing cutting-edge diagnostic tools to healthcare providers and eventually to patients.
• Contribution to Precision Medicine: The platform’s ability to provide detailed molecular insights aligns with the global shift towards personalized healthcare, where treatments are tailored to individual patient profiles.

Future Outlook

With the new capital, Senseera plans to:

• Advance Clinical Trials: Initiate and expand clinical studies to further validate the platform’s efficacy across various diseases and patient populations.
• Expand Partnerships: Develop collaborations with leading pharmaceutical companies that integrate the platform into drug development pipelines, allowing for greater accuracy and efficiency in clinical trials.
• Broaden Diagnostic Uses: Investigate other medical specialties, such as neurology and cardiovascular diseases, where the platform can be applied to address unsolved diagnostic challenges.

summary

A seed funding round of $7.1 million is a big step in the evolution of non-invasive diagnostics, and the company Senseera is on its way to revolutionizing the detection and monitoring of diseases with its GEM BIOMARKERS™ platform. This platform offers precise, biopsy-level insights through a simple blood test, thereby not only enhancing patient care but also accelerating the development of personalized therapies-a new era in precision medicine.